US2018094076A1PendingUtilityA1

Methods and Compositions for the Treatment of Autoimmune and Inflammatory Diseases

45
Assignee: LAURY KLEINTOP LISAPriority: Aug 10, 2011Filed: Dec 14, 2017Published: Apr 5, 2018
Est. expiryAug 10, 2031(~5.1 yrs left)· nominal 20-yr term from priority
Inventors:Lisa Laury-KleintopLaura Mandik-NayakGeorge C. PrendergastJames B. Duhadaway
A61P 37/06A61P 35/00A61P 3/10A61P 37/02A61P 29/00A61K 45/06C07K 14/00A61K 2039/505C07K 16/40C07K 7/08A61K 39/3955A61P 21/04C07K 7/06C07K 16/18A61K 2039/577A61K 39/0008A61K 2039/575C07K 14/40
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods for the treatment of autoimmune and inflammatory diseases are disclosed.

Claims

exact text as granted — not AI-modified
1 : A method for inhibiting an inflammatory or autoimmune disease or a condition or disorder associated with increased levels of immunoglobulin in the blood serum in a subject in need thereof, said method comprising administering at least one RhoB inhibitor to said subject. 
     
     
         2 : The method of  claim 1  comprising administering a composition comprising at least one RhoB inhibitor and at least one pharmaceutically acceptable carrier. 
     
     
         3 : The method of  claim 1 , wherein said RhoB inhibitor is a RhoB peptide. 
     
     
         4 - 9 . (canceled) 
     
     
         10 : The method of  claim 1 , wherein said method further comprises administering at least one anti-inflammatory agent. 
     
     
         11 : The method of  claim 1 , wherein said method further comprises the administration of at least immunosuppressant. 
     
     
         12 : The method of  claim 1 , wherein said inflammatory or autoimmune disease is at least partially autoantibody mediated. 
     
     
         13 : A composition comprising at least one antibody and at least one pharmaceutically acceptable carrier, wherein said antibody is immunologically specific for SEQ ID NO: 1, 2, 3, 5, 6, 7, or 8. 
     
     
         14 : The composition of claim  13 , wherein said antibody is immunologically specific for a polypeptide comprising SEQ ID NO: 3. 
     
     
         15 : The composition of  claim 13 , wherein said composition further comprises at least one anti-inflammatory agent. 
     
     
         16 : The composition of  claim 13 , wherein said composition further comprises at least one immunosuppressant. 
     
     
         17 : An isolated antibody immunologically specific for SEQ ID NO: 1, 2, 5, 6, 7, or 8. 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 : An isolated peptide having a sequence with at least 90% identity with SEQ ID NO: 1, 2, 5, 6, 7, or 8. 
     
     
         21 : A conjugate comprising the peptide of  claim 20  operably linked to carrier protein. 
     
     
         22 : A composition comprising at least one peptide of  claim 20  and at least one pharmaceutically acceptable carrier. 
     
     
         23 : The composition of  claim 22 , wherein said composition further comprises at least one anti-inflammatory agent. 
     
     
         24 : The composition of  claim 22 , wherein said composition further comprises at least one immunosuppressant. 
     
     
         25 : (canceled) 
     
     
         26 : The method of  claim 1 , wherein condition or disorder is hypergammaglobulinemia or monoclonal gammopathy of undetermined significance. 
     
     
         27 : The peptide of  claim 20  having a sequence with at least 90% identity with SEQ ID NO: 1. 
     
     
         28 : The peptide of  claim 20  consisting of SEQ ID NO: 1.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.